Casimiro Sandra, Guise Theresa A, Chirgwin John
Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisboa, Portugal.
Mol Cell Endocrinol. 2009 Oct 30;310(1-2):71-81. doi: 10.1016/j.mce.2009.07.004. Epub 2009 Jul 16.
Bone metastatic disease is a late-stage event of many common cancers, such as those of prostate and breast. It is incurable and causes severe morbidity. Tumor and bone interact in a vicious cycle, where tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines that act back on the tumor cells. Within the vicious cycle are many potential therapeutic targets for novel treatment of bone metastatic disease. Therapeutic strategies can be oriented to inhibit bone cells (osteoclasts and osteoblasts) or tumor responses to factors enriched in the bone microenvironment. Many publications, especially from pre-clinical animal models, show that this approach, especially combination treatments, can reduce tumor burden and tumor-derived bone lesions. This supports a novel paradigm: tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone.
骨转移性疾病是许多常见癌症（如前列腺癌和乳腺癌）的晚期表现。它无法治愈，会导致严重的发病率。肿瘤与骨骼在恶性循环中相互作用，肿瘤分泌的因子刺激骨细胞，骨细胞反过来释放生长因子和细胞因子，作用于肿瘤细胞。在这个恶性循环中有许多针对骨转移性疾病新治疗方法的潜在治疗靶点。治疗策略可以旨在抑制骨细胞（破骨细胞和成骨细胞）或肿瘤对骨微环境中富集因子的反应。许多出版物，特别是来自临床前动物模型的，表明这种方法，尤其是联合治疗，可以减轻肿瘤负担和肿瘤源性骨病变。这支持了一种新的模式：通过靶向骨骼及其微环境而不是单独靶向肿瘤本身，可以有效抑制肿瘤生长。
